

## Xbrane Biopharma Q1 2024 - Approaching an eventful second half of the year

Redeye returns with a research update following Xbrane's Q1 report. Sales and EBIT were lower than we had estimated, but end-customer sales grew 30%. The report prompts minor adjustments to our forecasts and valuation.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. [www.redeye.se/](http://www.redeye.se/)

### Attachments

---

[Xbrane Biopharma Q1 2024 - Approaching an eventful second half of the year](#)